Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
AJOONINSEAjooni Biotech Limited· Food ProductsHighNeutral
Announced Fri, 30 Jan, 2026 · 12:10 IST

Ajooni Biotech Q3 FY26 results: Revenue down 31% YoY, merger proposal deferred

Revenue DeclineResults View source PDFExplain this filing

AJOONI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.6%Reaction day
₹3.86
prior close
₹3.75
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.8%-0.3% vs market
Food Products peers, median of 89sector · industry level+0.5%+1.1% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 1.1 pts more than its Food Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+4.5
10m
+4.8
15m
+1.3
30m
+2.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.6+1.8-0.3+0.5+1.1
Next day
+10.6+0.5+10.1-0.5+11.1
2d
+10.4+4.3+6.1+2.1+8.3
3d
+23.8+5.6+18.2+3.1+20.7
4d
+34.7+4.6+30.1+2.9+31.8
5d
+28.2+3.8+24.5+1.5+26.7
1w
+33.7+7.5+26.2+2.7+30.9
15d
+24.9+3.8+21.1+2.1+22.8
1m
+3.6-0.3+3.9-3.3+7.0
2m
-0.3-9.6+9.3-13.8+13.6
3m
+9.6+9.9-0.3+3.1+6.5
UpDownMarket · Nifty Microcap 250Sector · Food Products peers, median of 89Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajooni Biotech Board approved unaudited Q3 FY26 results. Revenue from operations fell to Rs 5,875.33 lakhs versus Rs 8,541.75 lakhs in the year-ago quarter, a drop of around 31 percent. Net profit dipped to Rs 164.80 lakhs from Rs 182.82 lakhs. For nine months, revenue grew 6 percent to Rs 12,175.61 lakhs. Board also deferred a proposed merger with Healthy Biosciences pending further evaluation.

Likely market impact

Sharp 31 percent Q3 revenue drop may weigh on stock; merger deferral removes near-term corporate action trigger.